APOE4 reshapes the lipid droplet proteome and modulates microglial inflammatory responses
Open accessAbstract
Excess lipid droplet (LD) accumulation is implicated in various diseases, including Alzheimer's disease (AD), yet the mechanisms underlying this accumulation remain unclear. Apolipoprotein E (ApoE) is a droplet-associated protein, and its E4 variant confers the greatest genetic risk for late-onset AD while also being linked to increased neuroinflammation and LD accumulation. In this study, we compared the lipid and protein composition of hepatic LDs in targeted replacement mice expressing human E3 (neutral) or E4 (risk variant), under both baseline conditions and following lipopolysaccharide (LPS) administration. Lipidomic analysis revealed that E4 LDs exhibit a shift in glycerophospholipid distribution, with an increase in phosphatidylcholine species, such that their baseline profile resembles that of LPS-treated LDs. Quantitative proteomics indicated that E4 LDs are enriched in proteins related to vesicle transport but show decreased levels of proteins involved in fatty acid β-oxidation. Notably, many LD-associated proteins overlapped with those identified in AD postmortem and microglial 'omics studies, suggesting a role for LDs in AD pathogenesis. To further explore these findings, primary microglia from E3 and E4 mice were exposed to exogenous lipids, LPS, and necroptotic N2A cells. Under most conditions, E4 microglia accumulated more LDs and secreted higher levels of proinflammatory cytokines (TNF, IL-1β, IL-10) compared to E3 microglia, although their LPS response was blunted. These data suggest that altered LD dynamics in E4 microglia may contribute to the increased AD risk associated with APOE4.
AI snapshot
Written from the paper’s full text.
TL;DR
APOE4 expression reshapes hepatic lipid droplet lipid and protein composition, producing a baseline lipid profile that resembles LPS-treated E3 droplets and depleting fatty acid β-oxidation proteins. E4 primary microglia also accumulate more lipid droplets and secrete more proinflammatory cytokines under several stimuli, though their acute LPS cytokine response is blunted.
Key findings
- Lipidomic analysis of LD-enriched liver fractions found ~90% of the lipidome was triacylglycerols; E4 LDs showed increased phosphatidylcholine at baseline and after LPS, while E3 LDs significantly increased PC, PE, PI, and PS after LPS but E4 LDs did not.
- Proteomics identified 4,638 LD-enriched proteins and 2,338 “LD resident” proteins in the Results; E4 LDs were enriched for LD organization, membrane trafficking, and TG sequestration and depleted for fatty acid β-oxidation, with the WGCNA green-yellow metabolic module downregulated in E4 at baseline.
- AD/microglia dataset overlaps were high: 15/25 (60%) “incipient AD” proteins, 27/30 M4 microglial metabolism proteins, and ~35% of proteins upregulated in E4/4 AD brains overlapped with E4 LD-enriched proteins, versus ~29% for E3/3 AD and E3 LDs.
- E4 microglia accumulated significantly more LDs than E3 at baseline, OA alone, nN2A alone, and LPS alone (p < 0.05 for all), and secreted more TNF, IL-1β, and IL-10 at baseline and with OA; LPS-induced TNF and IL-10 release was blunted in E4 microglia.
Methods
- Twelve-month-old female human APOE3 or APOE4 targeted-replacement mice were injected with saline or LPS (5 mg/kg; n = 5 per group), and liver tissue was harvested after 24 h for density-gradient LD enrichment, TMT quantitative proteomics, and LC-MS/MS lipidomics.
- Proteomic data were analyzed with t-tests, Enrichr gene ontology, and WGCNA; lipidomic data used multiple-group t-tests with Benjamini-Hochberg FDR correction.
- Primary mouse microglia from E3/E4 pups were treated with oleic acid, LPS, necroptotic N2A cells, or combinations, then assessed by BODIPY imaging for LDs and V-plex assays for IL-1β, IFN-γ, TNF, IL-10, and IL-6.
Limitations
- Stated: LD enrichment may include transiently associated proteins rather than only true LD-resident proteins; only female mice were used; the study used a single 24 h LPS challenge, not chronic inflammation; and the main omics were performed on liver LDs rather than brain or microglial LDs.
- Stated: results differed from recent hiPSC experiments where inhibiting TG biosynthesis in E4 microglia blunted cytokine/chemokine release, possibly due to species differences in ApoE-receptor interactions and lipid processing.
- Evident from the text: the central lipidomic and proteomic conclusions rely on liver-derived LDs as a proxy for brain/microglia, so microglial relevance depends on cross-dataset overlap rather than direct brain LD profiling; no male mice or sex comparison was performed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
27 of 29 cited sources checked · 7 supported · 1 flagged · accuracy not yet measured
- Premisecitation
The effects of APOE on the composition of lipid droplets themselves remain unexplored.
“the effects of APOE on the composition of LDs themselves remains unexplored”
Quote in the paperSubstantial claim3 of 3 sources checked- cites Farmer et al., 2019 source
The Discussion says the link between E4 and lipid-droplet biology had not been widely explored, but does not identify droplet composition as an unexplored question. The Results examine droplet number, size, volume, and perilipin-2 expression; the passages found do not establish whether APOE’s effects on the composition of droplets themselves had been studied. (LLM, conf=0.70)
Experimental — accuracy not yet measured - cites Sienski et al., 2021 source
The Introduction reports that APOE4 astrocytes accumulated more unsaturated triacylglycerides stored in lipid droplets than APOE3 astrocytes, contrary to the unqualified claim that APOE’s effects on droplet composition remain unexplored. The Results clarify that the lipid composition was measured by whole-cell lipidomics, not by directly analyzing isolated droplets. (LLM, conf=0.76)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites Machlovi et al., 2022 source
The Results section on baseline E3 and E4 microglia reports differences in neutral-lipid levels and lipid-droplet abundance, but not the composition of the droplets themselves. A search for lipid-droplet composition found no passage stating that APOE’s effects on it remain unexplored; the absence of a composition analysis in this study does not establish that broader claim. No page numbers were available in our copy. (LLM, conf=0.72)
Experimental — accuracy not yet measured
- Premisecitation
Several in vivo studies of E4 mice and humans show an exaggerated response to inflammation in E4 individuals.
“several in vivo studies of E4 mice and humans show an exaggerated response to inflammation in E4 individuals (Vitek et al., 2009; Shi et al., 2017; Zhu et al., 2012; Gale et al., 2014).”
Quote in the paperNot a substantial claim3 of 3 sources checked- cites Vitek et al., 2009 source
The Discussion reports that LPS-injected APOE4/4 mice had greater increases in pro-inflammatory cytokine mRNA than APOE3/3 mice, and the Introduction cites other in vivo mouse studies with similar findings. Our copy discusses APOE4-associated human disease outcomes but does not report in vivo studies showing an exaggerated inflammatory response in humans. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites Shi et al., 2017 source
The mouse findings (section labeled Abstract; page not supplied) show greater neuroinflammation and microglial activation in ApoE4 mice with P301S tau pathology. The paper's direct test of inflammatory reactivity used cultured microglia, not an in vivo challenge, and its human findings concern disease progression rather than an inflammatory response. Thus it supports the mouse component in a specific tauopathy setting, but not the full claim as attributed to Shi et al. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites Zhu et al., 2012 source
- Findingcitation
~35% of proteins upregulated in E4/4 AD compared to E3/3 AD brains overlapped with proteins enriched on E4 LDs.
“~35 % of proteins upregulated in E4/4 AD compared to E3/3 AD brains (Dai et al., 2018) overlapped with proteins enriched on E4 LDs.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Dai et al., 2018 source
- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Premisecitation
ApoE is a droplet-associated protein found on the lipid droplet surface.
“ApoE is also droplet-associated protein found on the LD surface (Liu et al., 2023; Bersuker et al., 2018)”
Quote in the paperSubstantial claim2 of 2 sources checked- cites Liu et al., 2023 source
The Results sections report that apoE4 expression increases lipid droplet accumulation in microglia, but they do not establish that apoE protein is associated with droplets or located on their surface. Searches for apoE localization at the lipid droplet surface found no passage addressing that point. (LLM, conf=0.75)
Experimental — accuracy not yet measured - cites Bersuker et al., 2018 source
The Introduction describes proteins on the lipid-droplet surface, and the Results report identifying lipid-droplet proteins, but neither passage identifies ApoE. Searches for ApoE and apolipoprotein E found no passage in our copy establishing its presence on that surface. (LLM, conf=0.72)
Experimental — accuracy not yet measured
- Premisecitation
Women have increased susceptibility to E4 related phenotypes compared to men.
“women have increased susceptibility to E4 related phenotypes compared to men (Rajan et al., 2021; Yin et al., 2023)”
Quote in the paperSubstantial claim2 of 2 sources checked- cites Rajan et al., 2021 source
The Results section (‘Gender-Specific Number of People with Clinical AD from 2020 through 2060’; page unavailable) estimates more women than men living with clinical Alzheimer’s disease. It does not assess E4 status or whether women are more susceptible than men to E4-related phenotypes; searches for APOE ε4 and E4-related phenotypes found no such analysis. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites Yin et al., 2023 source
The Discussion (p. 14) reports a sex-dependent APOE4-associated impairment, with a pronounced reduction in astrocyte activation in females. The results (p. 9) also report APOE4-associated changes in males. These passages support a female-pronounced cellular phenotype in people with AD, but not the broader claim that women are more susceptible than men to E4-related phenotypes generally. (LLM, conf=0.84)
Experimental — accuracy not yet measured
- Findingown data
2099 overlapping proteins were identified and considered as LD-resident proteins by cross-referencing with six known lipid droplet proteomes.
“Upon cross-referencing our database with the six others, 2099 overlapping proteins were identified and considered as LD-resident proteins.”
Quote in the paperSubstantial claim3 of 3 sources checked- cites Liu et al., 2023 source
The Methods section describes RNA-sequencing analyses and staining lipid droplets, while the Results section reports lipid-droplet accumulation in microglia; page numbers are unavailable in our copy. Searches for “2099 overlapping proteins,” “six lipid droplet proteomes,” and “LD-resident proteins” found no passage describing the claimed proteome comparison or protein count. (LLM, conf=0.75)
Experimental — accuracy not yet measured - cites Olzmann & Carvalho, 2019 source
The ‘Protein targeting to lipid droplets’ section discusses lipid-droplet proteomes and estimates 100–150 high-confidence associated proteins in a prototypical mammalian cell, but does not report the claimed cross-reference or 2,099 overlapping proteins. Searches for ‘2099 overlapping proteins’ and for cross-referencing six proteomes found no passage addressing that result; the per-cell estimate is not a direct contradiction of a count pooled across proteomes. (LLM, conf=0.76)
Experimental — accuracy not yet measured - cites Mejhert et al., 2020 source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
- Findingown data
ACAT or DGAT inhibitors had minimal effect on cytokine output, outside of a dampened IFN-γ response following LD inhibition.
“outside of a dampened IFN-γ response following LD inhibition, ACAT or DGAT inhibitors had minimal effect on cytokine output.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
Preventing LD formation by inhibiting either ACAT1 or DGAT did not decrease cytokine output as expected.
“preventing LD formation by inhibiting either ACAT1 or DGAT did not decrease cytokine output as expected”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
Select proteins from the LD-microglia overlap (Apoe, SNX4, and Pla2g4a) co-localized with LDs in primary microglia cultures.
“we confirmed via immunocytochemistry that select proteins from our LD-microglia overlap (Apoe, SNX4, and Pla2g4a) co-localized with LDs in our primary microglia cultures”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
At baseline, E4-LDs showed an enrichment in PC that resembles the lipid profile of LPS-treated droplets.
“At baseline, E4-LDs showed an enrichment in PC that resembles the lipid profile of LPS-treated droplets.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingown data
DGAT1/ACAT1 inhibition failed to lower cytokine output in E4 microglia.
“DGAT1/ACAT1 inhibition failed to lower cytokine output in E4 microglia”
Quote in the paperSubstantial claim - Findingown data
Phosphatidylcholine was notably enriched in E4 compared to E3 LDs at baseline and in LPS-treated groups.
“Phosphatidylcholine (PC) was notably enriched in E4 compared to E3 LDs at baseline, as well as in LPS treated groups”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingown data
When stimulated with LPS, E3 microglia had a more robust cytokine response than E4 microglia.
“when stimulated with LPS, E3 microglia had a more robust cytokine response”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
The LPS-induced increase in liver lipid content was more robust in E3 than E4 livers, indicated by a significant interaction effect (F(1,8)=10.19; p=0.0128).
“a significant interaction effect (F (1,8) = 10.19; p = 0.0128) suggests this response more robust in E3 LPS livers compared to E4 LPS livers”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingown data
Cross-referencing with other known LD proteomes resulted in 2338 'LD resident' proteins that overlapped with at least one other dataset.
“which resulted in a total of 2338 ‘LD resident’ proteins which overlapped with at least one other dataset”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
Quantitative proteomic analyses of LD-containing fractions revealed a total of 4638 LD-enriched proteins.
“Quantitative proteomic analyses of the LD-containing fractions revealed at total of 4638 LD-enriched proteins”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
DGAT1 inhibition robustly suppressed LD accumulation across all conditions except nN2A.
“DGAT1 inhibition robustly suppressed LD accumulation across all conditions except nN2A”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingnone given
E4 LDs are depleted in fatty acid β-oxidation and oxidative phosphorylation proteins.
“as E4 LDs are depleted in fatty acid β-oxidation and oxidative phosphorylation proteins”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
15 out of 25 (60%) of the iAD AD-predictive proteins were highlighted in the LD proteome.
“Intriguingly, 15 out of 25 (60 %) of these AD-predictive proteins were highlighted in our LD proteome”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
The brown module featured hub proteins Nfkb2, Gbp3, and Rnf213, consistent with a transcriptional and antiviral response.
“The brown module, in particular, featured hub proteins like Nfkb2, Gbp3, and Rnf213, consistent with a transcriptional and antiviral response.”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingown data
In combined-stimulus conditions (OA + LPS and nN2A + LPS), the E4-E3 difference in LD accumulation was no longer significant.
“However, in the combined-stimulus conditions (OA + LPS and nN2A + LPS), the E4–E3 difference was no longer significant.”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
The top 30 most differentially expressed microglial transcripts from an AD mouse model corresponding to M4 showed near complete overlap (27 of 30 proteins) with the LD proteome.
“Notably, this list showed near complete overlap (27 of 30 proteins) with our LD proteome”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
LD composition and dynamics are modulated by APOE genotype.
“our findings demonstrate that LD composition and dynamics are modulated by APOE genotype.”
Quote in the paperSubstantial claim - Findingown data
Within genotypes, LPS caused enrichment of similar pathways in both E3 and E4 LDs, including interferon response and interleukin-6 signaling.
“Within genotypes, LPS caused enrichment of similar pathways in both E3 and E4 LDs. Specifically, this included enrichment of interferon response and interlukin-6 signaling pathway”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingown data
Blocking ACAT1 lowered IFN-γ secretion, particularly in E4 microglia.
“while blocking ACAT1 lowered IFN-γ secretion, particularly in E4 microglia”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
Under baseline, OA alone, nN2A alone, and LPS alone, E4 microglia accumulated significantly more LDs than E3 microglia (p<0.05 for all).
“Under baseline, OA alone, nN2A alone, and LPS alone, E4 microglia accumulated significantly more LDs than E3 (E4 vs. E3: p < 0.05 for all).”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
The LD-enriched proteome shows high overlap with multiple AD/APOE4/microglia proteomic and transcriptomic datasets.
“an exciting finding from our profiling of LD-enriched liver fractions was a surprisingly high overlap with multiple AD/APOE4/microglia proteomic and transcriptomic datasets.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
E4 cells show increased cytokine output relative to E3 at baseline.
“we did observe an increase in cytokine output from E4 cells relative to E3 at baseline.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
Total cholesterol ester content decreased more robustly in E3 LDs following LPS treatment compared to E4 LDs.
“the total abundance of ChE content decreased more robustly in E3 LDs following LPS treatment compared to the E4 LDs”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingreasoning
The overlap of LD proteins with AD datasets points toward a depletion of FA β-oxidation on E4 relative to E3 LDs.
“in each case above, gene ontology of these shared LD-AD proteins pointed toward a depletion of FA β-oxidation on E4 relative to E3 LDs.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Findingown data
ACAT1 inhibition significantly reduced LD formation in all conditions except OA.
“ACAT1 inhibition significantly reduced LD formation in all conditions except OA”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Findingown data
Following LPS treatment, the proteome comparison between E4 and E3 LDs reflected differences in the type of immune proteins localized to the LD surface.
“Following LPS treatment, a comparison of the proteome between E4 and E3 LDs reflected differences in the type of immune proteins localized to the LD surface”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingown data
Both E3 and E4 liver tissue increased lipid content after LPS stimulation.
“Both E3 and E4 liver tissue increased lipid content after LPS stimulation”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Findingcitation
These results differ from recent experiments using similar methods in hiPSC (Stephenson et al., 2024), where inhibiting TG biosynthesis in E4 microglia blunted cytokine/chemokine release and attenuated the disease-associated transcriptional profile.
“these results differ from recent experiments using similar methods in human induce pluripotent stem cells (hiPSC) (Stephenson et al., 2024), where inhibiting TG biosynthesis in E4 microglia blunted cytokine/chemokine release and attenuated the disease-associated transcriptional profile of these cells.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Stephenson et al., 2024
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
The E4-associated depletion of FA β-oxidation proteins on LDs is supported by proteomics GO and WGCNA results.
“This line of thinking is bolstered by the proteomics gene ontology and WGCNA results which showed a depletion of FA β-oxidation proteins on the E4 LDs relative to E3.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Study design and conductreasoning
Due to the nature of the LD enrichment, proteins that are not truly LD-resident (including those that transiently associate with LDs) are likely included in the analyses.
“due to the nature of the LD enrichment, some proteins that transiently associate with LDs may have been included in the analysis.”
- Also stated in: § Discussion · hedged
“proteins that are not truly LD “resident” (i.e. wholly embedded within the LD phospholipid shell) are likely included in our analyses.”
Quote in the paperNot a substantial claim - Also stated in: § Discussion · hedged
- Interpretationown data
Many AD-implicated proteins are LD-resident, based on integration of the novel APOE-LD proteome with previous AD and microglia datasets.
“Integration of our novel APOE-LD proteome with previous AD and microglia datasets further suggests that many AD-implicated proteins are LD-resident”
Quote in the paperSubstantial claim - Interpretationown data
The E3 vs E4 response to an inflammatory challenge features varying LD protein dynamics.
“these results show that i) the E3 vs E4 response to an inflammatory challenge features varying LD protein dynamics”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Interpretationown data
Many of the same proteins that define AD pathogenesis are found on or closely associated with LDs.
“suggesting that many of the same proteins that define AD pathogenesis are found on or closely associated with LDs.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Interpretationown data
The E4 LD is enriched for proteins that facilitate lipid storage over utilization.
“ii) the E4 LD is enriched for proteins that facilitate lipid storage over utilization.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Interpretationown data
E4's influence on LDs could be cell type agnostic.
“This suggest that E4s influence on LDs could be cell type agnostic”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Study design and conductreasoning
The study only utilized female mice.
“this study only utilized female mice.”
Quote in the paperSubstantial claim- Rests on an assumption: Women are disproportionately affected by AD compared to men.
- Interpretationown data
Many previously implicated AD/E4 proteins are LD-associated.
“our data suggest that many of these previously implicated proteins are LD-associated.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Interpretationown data
LDs may serve as a central hub for immunometabolic signaling in glia.
“supporting a model in which LDs may serve as a central hub for immunometabolic signaling in glia.”
Quote in the paperSubstantial claim - Interpretationown data
LDs from humanized E4 mice have a distinct lipid and protein profile compared to E3 droplets, both at baseline and following an acute inflammatory challenge.
“We show that LDs from humanized E4 mice have a distinct lipid and protein profile compared to E3 droplets, both at baseline and following an acute inflammatory challenge.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Interpretationown data
Inhibition of LD formation is largely insufficient to reduce cytokine production.
“our results suggest that inhibition of LD formation is largely insufficient to reduce cytokine production”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
- Study design and conductown data
The LD-enriched fractions from E3/E4 mouse liver are a validated APOE-specific source material for downstream proteomic and lipidomic analysis.
“Together, these data validate an APOE-specific, LD-enriched source material for downstream analysis of the proteome and lipidome.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Study design and conductreasoning
The single 24 h LPS challenge does not model the sustained neuroinflammation characteristic of AD.
“it does not model the sustained neuroinflammation characteristic of AD.”
Quote in the paperNot a substantial claim
- Classified as probably not a substantial claim. 15
- May combine two claims. 25
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationExcess lipid droplet accumulation is associated with several diseases, including Alzheimer's disease.
“It is well documented that several diseases are associated with excessive LDs, including but not limited to obesity, atherosclerosis, cancer, type 2 diabetes, and Alzheimer’s disease (AD) (Farmer et al., 2020; Dalhaimer, 2019)”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites Farmer et al., 2020 source
The Alzheimer’s Disease section (page unavailable) reports increased lipid-droplet formation in both human AD samples and an AD mouse model. The Introduction also links lipid droplets to obesity-related dysfunction and insulin resistance. The cited passages do not establish the sentence’s additional associations with atherosclerosis, cancer, or specifically type 2 diabetes. (LLM, conf=0.84)
Experimental — accuracy not yet measured - cites Dalhaimer, 2019 source
In “Lipid Droplets in Disease” (page unavailable), Dalhaimer links lipid droplets to obesity, type 2 diabetes, Alzheimer’s disease, cardiovascular disease, and cancer. The section also reports increased small lipid droplets in APOE4-expressing astrocytes. It does not establish excessive lipid droplet accumulation across every disease in the citing sentence, particularly atherosclerosis. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim.
PremisecitationThe M4 network module is related to microglial metabolism in human AD brain.
“Another proteomic analyses of human AD brain identified a network module related to microglial metabolism (termed “M4”) (Johnson et al., 2020).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Johnson et al., 2020 source
Classified as probably not a substantial claim.
PremisecitationFatty acid β-oxidation and oxidative phosphorylation pathways support energy-intensive immune responses.
“pathways that support energy-intensive immune responses (Orihuela et al., 2016; Mills et al., 2017)”
Quote in the paperSubstantial claim1 of 2 sources checkedClassified as probably not a substantial claim.
PremisecitationThe iAD signature is a set of proteins highly expressed in young E4 carrier brains but reduced in AD brains.
“The iAD signature is a set of proteins highly expressed in young E4 carrier brains but reduced in AD brains (Roberts et al., 2021).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Roberts et al., 2021 source
The Results (Stage 1: Discovery of the incipient AD signature) identify 25 signature proteins and report that nearly all were increased in young APOE ε4 carriers relative to noncarriers and reduced in AD relative to controls. The claim omits exceptions: one protein was reduced in young carriers, and TBP did not show a consistent direction across the two AD cohorts. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationPrimary mouse microglia expressing human E4 exhibit changes in morphology and increased cytokine production associated with LD accumulation compared to E3 microglia.
“Machlovi et al. previously showed that primary mouse microglia expressing human E4 exhibit changes in morphology and increased cytokine production associated with LD accumulation compared to E3 microglia (Machlovi et al., 2022).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Machlovi et al., 2022 source
May combine two claims.
PremisecitationE4-expressing astrocytes and E4 microglia accumulate more lipid droplets than E3-expressing cells.
“E4 expressing astrocytes (Windham et al., 2024; Farmer et al., 2019; Sienski et al., 2021) and E4 microglia (Machlovi et al., 2022; Victor et al., 2022; Haney et al., 2024) both accumulate more lipid droplets than neutral AD-risk ε3/ε3 (E3) expressing cells.”
Quote in the paperSubstantial claim3 of 3 sources checked- cites Windham et al., 2024 source
The Results section (‘APOE4 expression results in large LDs with impaired turnover’; page unavailable) reports greater total lipid-droplet area in E4 than E3 astrocytes after an oleic-acid pulse-chase. It does not report more droplets: droplet number was the same after the chase and lower in E4 cells immediately after the pulse. The Windham citation is attached to the astrocyte part of the sentence, not the microglia part. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites Farmer et al., 2019 source
- cites Sienski et al., 2021 source
Classified as probably not a substantial claim.
PremisecitationAPOE4 has been reported to impair TLR4 trafficking and downstream signaling in myeloid cells.
“APOE4 has been reported to impair TLR4 trafficking and downstream signaling in myeloid cells (Vitek et al., 2009; Liu et al., 2023)”
Quote in the paperSubstantial claim2 of 2 sources checked- cites Vitek et al., 2009 source
The Discussion (page not provided) reports altered NF-κB and p38 MAP kinase signaling in APOE4-expressing immune cells, so it supports an effect on signaling. It does not describe impaired TLR4 trafficking or establish impaired TLR4-specific downstream signaling; the NF-κB activity it discusses is increased, not decreased. (LLM, conf=0.84)
Experimental — accuracy not yet measured - cites Liu et al., 2023 source
The Results section on APOE isoform-dependent transcriptomic signatures reports that apoE4 fails to activate, or has the opposite effect on, several immune-response pathways in microglia. That supports impaired myeloid-cell responsiveness broadly, but the passages found do not address TLR4 trafficking or TLR4-specific downstream signaling (searched: TLR4 trafficking, TLR4, and toll-like receptor 4 signaling). (LLM, conf=0.82)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationCarriage of the APOE4 allele is associated with increased neuroinflammation and metabolic disturbances within neurons and glial cells.
“carriage of the E4 allele is associated with increased neuroinflammation and metabolic disturbances within neurons and glial cells (Krasemann et al., 2017)”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Krasemann et al., 2017 source
The Results section on the MGnD phenotype reports that APOE signaling induces an inflammatory program in microglia, supporting a link between APOE and neuroinflammation. But the cited passages do not identify the APOE4 allele specifically or report metabolic disturbances within neurons and glial cells; the paper’s findings about APOE generally cannot establish those parts of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataSoft power β = 6 was chosen for WGCNA, at which the scale-free fit index exceeded 0.85 while preserving adequate mean connectivity.
“Soft power β = 6 was chosen via the pickSoftThreshold function, at which the scale-free fit index (Olzmann and Carvalho, 2019) exceeded 0.85, while preserving adequate mean connectivity.”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Olzmann and Carvalho, 2019 source
The cited paper’s lipid-droplet contact-sites section discusses proteins involved in droplet fusion, not WGCNA. Searches for pickSoftThreshold, β = 6, the scale-free fit index, and mean connectivity found no passage addressing the claimed threshold choice; the copy provides no page numbers. (LLM, conf=0.78)
Experimental — accuracy not yet measured
May combine two claims.
Findingown dataThe bulk of lipid content in LD-enriched fractions was composed of glycerolipid, with ~90% of the lipidome consisting of triacylglycerols.
“the bulk of lipid content in LD enriched fractions was composed of glycerolipid, with ~90 % of the lipidome consisting of triacylglycerols (TGs)”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
May combine two claims.
Findingown dataThe brown and purple WGCNA modules were upregulated by LPS across genotypes and enriched for processes including innate immune response, glycogen metabolism, and protein or vesicle trafficking.
“the brown and purple modules were upregulated by LPS across genotypes and enriched for processes including innate immune response, glycogen metabolism, and protein or vesicle trafficking”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
May combine two claims.
Findingown dataE4 microglia secreted more TNF, IL-1β and IL-10 than E3 at baseline, as well as when exposed to OA.
“E4 microglia secreted more TNF, IL-1β and IL-10 than E3 at baseline, as well as when exposed to OA.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
May combine two claims.
Findingown dataUnder basal conditions, E4 LDs were enriched for proteins involved in LD organization, membrane trafficking, and TG sequestration, while relatively depleted in proteins related to fatty acid β-oxidation.
“under basal conditions, E4 LDs were enriched for proteins involved in LD organization, membrane trafficking, and TG sequestration, while they were relatively depleted in proteins related to fatty acid β-oxidation”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
May combine two claims.
Findingown dataE3 LDs showed enrichment for fatty acid metabolism and oxidative phosphorylation pathways in both saline and LPS treatment when compared to E4, which showed enrichment in inflammatory response and complement pathway in the saline or LPS comparison respectively.
“E3 LDs showed enrichment for fatty acid metabolism and oxidative phosphorylation pathways in both saline and LPS treatment when compared to E4, which showed enrichment in inflammatory response and complement pathway in the saline or LPS comparison respectively”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
May combine two claims.
Findingown dataE3 droplets increase their PC content when stimulated with LPS, whereas E4 droplets do not show a similar response.
“while E3 droplets increase their PC content when stimulated with LPS, a similar response is not observed in E4 droplets”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
May combine two claims.
Findingown dataIn E3 LDs, LPS significantly increased the percentage of PC, PE, PI, and PS, but these LPS-dependent increases were not observed in E4 LDs.
“A comparison of the E3 Saline to E3 LPS LD lipidome showed significant increase in the percentage of PC, PE, PI, and PS; however, these same LPS-dependent increases were not observed in the E4 LD lipidome”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
May combine two claims.
Findingown dataAddition of LPS resulted in a dramatic increase in release of TNF, IL-1β, and IL-10 in control, OA, and nN2A treated cells; however, this effect was blunted in E4 microglia for TNF and IL-10.
“the addition of LPS resulted in a dramatic increase in the release of these cytokines in control, OA, and nN2A treated cells; however, this effect was blunted in E4 microglia for TNF and IL-10”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
May combine two claims.
Findingown dataIn response to nN2A, E4 microglia secreted more TNF and IL-1β, but not IL-10, than E3.
“In response to nN2A, E4 secreted more TNF and IL-1β, but not IL-10.”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
May combine two claims.
Findingown dataThe green-yellow WGCNA module was significantly downregulated in E4 LDs at baseline and was enriched for metabolic pathways including fatty acid β-oxidation, branched-chain amino acid catabolism, and the TCA cycle.
“the green-yellow module was significantly downregulated in E4 LDs at baseline and was enriched for metabolic pathways, including fatty acid β-oxidation, branched-chain amino acid catabolism, and the TCA cycle”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
May combine two claims.
Findingown data~29% of proteins upregulated in E3/3 AD compared to E4/4 AD brains overlapped with proteins enriched on E3 LDs and were associated with pathways of fatty acid β-oxidation.
“~29 % of proteins upregulated in E3/3 AD compared to E4/4 AD brains overlapped with proteins enriched on E3 LDs and were associated with pathways of fatty acid β-oxidation”
Quote in the paperNot a substantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
May combine two claims.
Findingown dataIn both saline and LPS treated conditions, the overlap of LD proteins and microglial genes differentially regulated by E4 pointed to upregulation of pathways of protein synthesis and transport along with concomitant downregulation of fatty acid metabolism.
“In both the saline and LPS treated conditions, the overlap of LD proteins and microglial genes differentially regulated by E4 pointed to an upregulation of pathways of protein synthesis and transport along with a concomitant downregulation of fatty acid metabolism”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
May combine two claims.
Findingown dataIn E3 LDs, LPS significantly decreased the abundance of polyunsaturated and monounsaturated fatty acids on TGs and cholesterol esters, while no change was observed between E4 groups.
“the abundance of polyunsaturated fatty acids (PUFA) and monounsaturated fatty acids (MUFA) are significantly decreased between E3 saline and E3 LPS, but no change is observed between the E4 groups”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
Probably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataProteomics analysis detected 6192 proteins.
“Proteomics analysis detected 6192 proteins.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataAn outlier analysis revealed 28 statistical outliers among the 6420 total values (0.4% outliers).
“which revealed 28 statistical outliers among the 6420 total values (321 metabolites × 20 samples; 0.4 % outliers).”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Findingown dataA final 4267 proteins were included and analyzed after filtering for more than two unique peptides and a 5% false discovery rate.
“Proteins were accepted if they contained more than two unique peptides and were within the false discovery rate of 5 %. A final 4267 proteins were included and analyzed.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataLipidomic analysis revealed 321 unique lipid metabolites.
“Lipidomic analysis revealed 321 unique lipid metabolites.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningNeuronal debris-derived lipids are likely routed into alternative esterification pathways, such as ACAT-mediated cholesterol esterification, phospholipid remodeling via the Lands' cycle, and/or DGAT2-derived TAG synthesis.
“suggesting that neuronal debris–derived lipids are likely routed into alternative esterification pathways, such as ACAT-mediated cholesterol esterification, phospholipid remodeling via the Lands’ cycle, and/or DGAT2-derived TAG synthesis”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
May combine two claims.
Interpretationown dataE3 microglia maintain a more catabolic, oxidative lipid metabolic state, while E4 microglia exhibit reduced mitochondrial engagement even in the absence of stimulation.
“suggesting that E3 microglia maintain a more catabolic, oxidative lipid metabolic state, while E4 microglia exhibit reduced mitochondrial engagement even in the absence of stimulation”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
May combine two claims.
Interpretationown dataE4-expressing microglia accumulate more LDs and secrete higher levels of cytokines at baseline.
“Together, these data suggest that E4-expressing microglia accumulate more LDs and secrete higher levels of cytokines at baseline”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
May combine two claims.
Interpretationown dataE4 expressing microglia accumulate more LDs and secrete more cytokines following various stimuli.
“we also show that E4 expressing microglia accumulate more LDs and secrete more cytokines following various stimuli.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenThe APOE ε4/ε4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease.
“The strongest of the LOAD risk genes is the ε4/ε4 (E4) allele of Apolipoprotein E (APOE)”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataUnlike E3 LDs, which substantially remodel their lipidome in response to an inflammatory challenge, E4 LDs show a blunted response and display an intermediate lipid profile between baseline E3 and the post-inflammatory state.
“These results suggest that unlike E3 LDs, which substantially remodel their lipidome in response to an inflammatory challenge, E4 LDs show a blunted response and display an intermediate lipid profile between baseline E3 and the post-inflammatory state.”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
May combine two claims.
Interpretationown dataThe protein composition of liver-derived LDs, and the effect of E4 in modulating enrichment of these proteins, substantially overlaps with the established E4/AD proteome and are present on microglia LDs.
“Together, these data show the protein composition of liver-derived LDs – and the effect of E4 in modulating enrichment of these proteins – substantially overlaps with the established E4/AD proteome and are present on microglia LDs”
Quote in the paperSubstantial claim- Rests on an assumption: Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
- Rests on an assumption: Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenProcedures concerning mice were in compliance with the University of Kentucky's Institutional Animal Care and Use Committee.
“Procedures concerning mice were in compliance with the University of Kentucky’s Institutional Animal Care and Use Committee.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataWGCNA modules showed high intramodular connectivity and module cohesion, with mean |kME| values ranging from 0.80 to 0.83 and 56-74% of genes per module classified as hubs.
“Across all modules, mean |kME| values ranged from 0.80 to 0.83 and 56–74 % of genes per module were classified as hubs, demonstrating high intramodular connectivity and module cohesion.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Study design and conductown dataMetabolite abundance averages were calculated within groups and multiple group t-tests were performed with Benjamini-Hochberg FDR correction.
“Metabolite abundance averages were calculated within groups and multiple group t-tests were performed on the entire data set followed by post-hoc multiple comparisons correction for false discovery rate (FDR) using Benjamini-Hochberg (BH) adjustment.”
Quote in the paperSubstantial claim
The paper relies on this without support.
Targeted replacement mice expressing human E3 or E4 are a valid model of human APOE isoform-specific biology.
“targeted replacement mice expressing human E3 (neutral) or E4 (risk variant)”
The paper relies on this without support.
LPS administration in mice models an inflammatory challenge relevant to AD neuroinflammation.
“following lipopolysaccharide (LPS) administration”
The paper relies on this without support.
Primary microglia cultures from E3 and E4 mice reflect microglial behavior in vivo.
“primary microglia from E3 and E4 mice were exposed to exogenous lipids, LPS, and necroptotic N2A cells”
The paper relies on this without support.
Lipid droplets protect against lipotoxicity and buffer ROS.
“because lipid droplets also protect against lipotoxicity and buffer ROS”
The paper relies on this without support.
Women are disproportionately affected by AD compared to men.
“women are disproportionately affected by AD compared to men.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
APOE genotype influences the inflammatory response, with E4 expression linked to significantly higher cytokine levels in both humans and mice compared to E3 or E2.
“In addition to metabolic dysregulation, APOE genotype also influences the inflammatory response, with E4 expression linked to significantly higher cytokine levels in both humans and mice compared to E3 or E2”
From Older adult APOE4 mice exhibit modest immunometabolic adaptation following microglial APOE2 replacement (2027) · cites this paper as Friday et al., 2025
The Results report higher cytokine secretion by E4 than E3 mouse microglia at baseline and under some treatments. The Discussion also cites studies showing exaggerated inflammatory responses in E4 mice and humans, but it does not establish significantly higher cytokine levels in humans or compare E4 with E2. It notes that E3 microglia had a stronger response to LPS, so the direction depends on the condition. (LLM, conf=0.89)
Experimental — accuracy not yet measuredBoth cell type and cellular environment modulate the lipid droplet proteome and lipidome.
“Importantly, both cell type and cellular environment modulate the lipid droplet proteome and lipidome3–9.”
From APOE genotypes differentially remodel the astrocytic lipid droplet proteome to shape lipid droplet dynamics (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Conflicting totals for proteins included in the LD proteome
MajorThe Results report 4,638 LD-enriched proteins, but the Methods say 4,267 proteins passed the acceptance criteria and were included in the analysis. These are presented as the analyzed proteome without an explanation for the different totals.
“Quantitative proteomic analyses of the LD-containing fractions revealed at total of 4638 LD-enriched proteins”
“A final 4267 proteins were included and analyzed.”
Conflicting counts of LD-resident proteins
MajorThe Results give 2,338 proteins overlapping another LD dataset, while the Methods give 2,099 for the same cross-referencing step.
“a total of 2338 ‘LD resident’ proteins which overlapped with at least one other dataset”
“Upon cross-referencing our database with the six others, 2099 overlapping proteins were identified and considered as LD-resident proteins.”
Female-only limitation conflicts with unsexed microglia donors
MinorThe Discussion says the study used only female mice, but the Methods state that pups supplying primary microglia were not genotyped for sex chromosomes. The female-only claim therefore is not established for those experiments.
“Second, this study only utilized female mice.”
“Littermates were pooled together to increase cell counts, but pups from the same litter were not genotyped for sex chromosomes.”
N2A stimulus is called both necroptotic and apoptotic
MinorThe experiments describe treatment with necroptotic N2A cells, but the preparation method says apoptotic cells were collected for use. Those terms identify different cell-death states for a conclusion-bearing stimulus.
“Microglia were treated with exogenous fatty acid (OA), LPS, necroptotic N2A cells (nN2A), or combinations thereof”
“Cells began to detach from the flasks and all apoptotic cells and media were collected, split into 8 × 106 cells/ml aliquots and frozen for later use.”
Cites
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · see citing works
Dynamics and functions of lipid droplets
Olzmann, J. A., & Carvalho, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0085-z · Cited by 2,740 · see citing works
Microglial <scp>M1/M2</scp> polarization and metabolic states
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13139 · Cited by 2,070 · see citing works
Lipid Droplets and Cellular Lipid Metabolism
Walther, T. C., & Farese, R. V. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061009-102430 · Cited by 1,668 · see citing works
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455 · see citing works
Marschallinger, J., Iram, T., Zardeneta, M., Lee, S. E., Lehallier, B., Haney, M. S., Pluvinage, J. V., Mathur, V., Hahn, O., Morgens, D. W., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-019-0566-1 · Cited by 1,384 · cited 3× · see citing works
“Lipids within LDs can be liberated to become mediators of inflammation, and in aging and AD, lipid droplets accumulate in microglia and cytokine production increases (Jarc and Petan, 2020; Haney et al., 2024; Marschallinger et al., 2020).”
Self-citationGene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344 · see citing works
Rajan, K. B., Weuve, J., Barnes, L. L., McAninch, E. A., Wilson, R. S., & Evans, D. A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12362 · Cited by 1,268 · see citing works
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · see citing works
Mitochondria are the powerhouses of immunity
Mills, E. L., Kelly, B., & O'Neill, L. A. J. (2017) · Nature Immunology · doi:10.1038/ni.3704 · Cited by 1,161 · see citing works
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001 · see citing works
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · see citing works
Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity
Ioannou, M. S., Jackson, J., Sheu, S.-H., Chang, C.-L., Weigel, A. V., Liu, H., Pasolli, H. A., Xu, C. S., Pang, S., Matthies, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.001 · Cited by 760 · see citing works
Lipid droplets and liver disease: from basic biology to clinical implications
Gluchowski, N. L., Becuwe, M., Walther, T. C., & Farese, R. V. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.32 · Cited by 675 · see citing works
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · see citing works
Johnson, E. C. B., Carter, E. K., Dammer, E. B., Duong, D. M., Gerasimov, E. S., Liu, Y., Liu, J., Betarbet, R., Ping, L., Yin, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00999-y · Cited by 561 · see citing works
APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia
Haney, M. S., Pálovics, R., Munson, C. N., Long, C., Johansson, P. K., Yip, O., Dong, W., Rawat, E., West, E., Schlachetzki, J. C. M., et al. (2024) · Nature · doi:10.1038/s41586-024-07185-7 · Cited by 536 · cited 6× · see citing works
“Another recent study showed that E4/4 iMGs had significantly greater LD accumulation compared with isogenic E3/3 iMGs, and restoration of cytokines was achieved with by lowering LD load through PIK3CA inhibition (Haney et al., 2024).”
InfluentialKrahmer, N., Guo, Y., Wilfling, F., Hilger, M., Lingrell, S., Heger, K., Newman, H. W., Schmidt‐Supprian, M., Vance, D. E., Mann, M., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.013 · Cited by 530 · see citing works
Wang, H., Sreenivasan, U., Hu, H., Saladino, A. J., Polster, B. M., Lund, L. M., Gong, D., Stanley, W. C., & Sztalryd, C. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m017939 · Cited by 486 · see citing works
Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense
Bosch, M., Sánchez-Álvarez, M., Fajardo, A., Kapetanovic, R., Steiner, B., Dutra, F., Moreira, L., López, J. A., Campo, R., Marí, M., et al. (2020) · Science · doi:10.1126/science.aay8085 · Cited by 480 · see citing works
Molecular mechanisms of endotoxin tolerance
Fan, H., & Cook, J. A. (2004) · Journal of Endotoxin Research · doi:10.1179/096805104225003997 · Cited by 430 · see citing works
Cholesterol and matrisome pathways dysregulated in astrocytes and microglia
TCW, J., Qian, L., Pipalia, N. H., Chao, M. J., Liang, S. A., Shi, Y., Jain, B. R., Bertelsen, S. E., Kapoor, M., Marcora, E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.017 · Cited by 411 · see citing works
Guo, Y., Cordes, K. R., Farese, R. V., & Walther, T. C. (2009) · Journal of Cell Science · doi:10.1242/jcs.037630 · Cited by 402 · see citing works
ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism
Qi, G., Mi, Y., Shi, X., Gu, H., Brinton, R. D., & Yin, F. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108572 · Cited by 379 · see citing works
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02931-w · Cited by 369 · see citing works
APOE genotype-specific differences in the innate immune response
Vitek, M. P., Brown, C. M., & Colton, C. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.014 · Cited by 362 · see citing works
Lipid droplet size directs lipolysis and lipophagy catabolism in hepatocytes
Schott, M. B., Weller, S. G., Schulze, R. J., Krueger, E. W., Drizyte-Miller, K., Casey, C. A., & McNiven, M. A. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201803153 · Cited by 348 · see citing works
Bersuker, K., Peterson, C. W. H., To, M., Sahl, S. J., Savikhin, V., Grossman, E. A., Nomura, D. K., & Olzmann, J. A. (2018) · Developmental Cell · doi:10.1016/j.devcel.2017.11.020 · Cited by 346 · see citing works
Plubell, D. L., Wilmarth, P. A., Zhao, Y., Fenton, A. M., Minnier, J., Reddy, A. P., Klimek, J. E., Yang, X., David, L. L., & Pamir, N. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.065524 · Cited by 337 · see citing works
<i>APOE4</i> disrupts intracellular lipid homeostasis in human iPSC-derived glia
Sienski, G., Narayan, P., Bonner, J. M., Kory, N., Boland, S., Arczewska, A. A., Ralvenius, W. T., Akay, L., Lockshin, E., He, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4564 · Cited by 336 · see citing works
Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity
Victor, M. B., Leary, N., Luna, X., Meharena, H. S., Scannail, A. N., Bozzelli, P. L., Samaan, G., Murdock, M. H., von Maydell, D., Effenberger, A. H., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.005 · Cited by 316 · see citing works
Lipid Droplets in Health and Disease
Önal, G., Kutlu, O., Gozuacik, D., & Emre, S. D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0521-7 · Cited by 279 · see citing works
Lipid droplets in neurodegenerative disorders
Farmer, B. C., Walsh, A. E., Kluemper, J. C., & Johnson, L. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00742 · Cited by 270 · see citing works
Self-citationAPOE genotype alters glial activation and loss of synaptic markers in mice
Zhu, Y., Nwabuisi‐Heath, E., Dumanis, S. B., Tai, L. M., Yu, C., Rebeck, G. W., & Ladu, M. J. (2012) · Glia · doi:10.1002/glia.22289 · Cited by 224 · see citing works
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211 · see citing works
Lee, S., Devanney, N. A., Golden, L. R., Smith, C. T., Schwartz, J. L., Walsh, A. E., Clarke, H. A., Goulding, D. S., Allenger, E. J., Morillo-Segovia, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112196 · Cited by 203 · see citing works
Self-citationAPOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints
Yin, Z., Rosenzweig, N., Kleemann, K. L., Zhang, X., Brandão, W., Margeta, M. A., Schroeder, C., Sivanathan, K. N., Silveira, S., Gauthier, C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01627-6 · Cited by 202 · see citing works
APOε4 is associated with enhanced in vivo innate immune responses in human subjects
Gale, S. C., Gao, L., Mikacenic, C., Coyle, S. M., Rafaels, N., Murray Dudenkov, T., Madenspacher, J. H., Draper, D. W., Ge, W., Aloor, J. J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.032 · Cited by 202 · see citing works
The role of innate immune genes in Alzheimer's disease
Griciuc, A., & Tanzi, R. E. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000911 · Cited by 191 · see citing works
Krahmer, N., Najafi, B., Schueder, F., Quagliarini, F., Steger, M., Seitz, S., Kasper, R., Salinas, F., Cox, J., Uhlenhaut, N. H., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.09.017 · Cited by 188 · see citing works
A twist of FATe: Lipid droplets and inflammatory lipid mediators
Jovičić, E. J., & Petan, T. (2019) · Biochimie · doi:10.1016/j.biochi.2019.11.016 · Cited by 177 · see citing works
Miner, G. E., So, C. M., Edwards, W. D., Ragusa, J. V., Wine, J. T., Gutierrez, D. W., Airola, M. V., Herring, L. E., Coleman, R., Klett, E. L., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.006 · Cited by 167 · see citing works
Self-citationApoE4 upregulates the activity of mitochondria‐associated ER membranes
Tambini, M. D., Pera, M., Kanter, E., Yang, H., Guardia‐Laguarta, C., Holtzman, D., Sulzer, D., Area‐Gomez, E., & Schon, E. A. (2016) · The EMBO Reports · doi:10.15252/embr.201540614 · Cited by 166 · see citing works
Apolipoprotein E4 Alters Astrocyte Fatty Acid Metabolism and Lipid Droplet Formation
Farmer, B., Kluemper, J., & Johnson, L. (2019) · Cells · doi:10.3390/cells8020182 · Cited by 164 · see citing works
Self-citationLiu, C.-C., Wang, N., Chen, Y., Inoue, Y., Shue, F., Ren, Y., Wang, M., Qiao, W., Ikezu, T. C., Li, Z., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01640-9 · Cited by 146 · see citing works
Lipke, K., Kubis-Kubiak, A., & Piwowar, A. (2022) · Cells · doi:10.3390/cells11050844 · Cited by 145 · see citing works
Mejhert, N., Kuruvilla, L., Gabriel, K. R., Elliott, S. D., Guie, M.-A., Wang, H., Lai, Z. W., Lane, E. A., Christiano, R., Danial, N. N., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.014 · Cited by 121 · see citing works
Johnson, L. A., Olsen, R. H. J., Merkens, L. S., DeBarber, A. E., Steiner, R. D., Sullivan, P. M., Maeda, N., & Raber, J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.016 · Cited by 105 · see citing works
Self-citationAPOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size
Windham, I. A., Powers, A. E., Ragusa, J. V., Wallace, E. D., Zanellati, M. C., Williams, V. H., Wagner, C. H., White, K. K., & Cohen, S. (2024) · Journal of Cell Biology · doi:10.1083/jcb.202305003 · Cited by 96 · see citing works
Self-citationGuo, J. L., Braun, D., Fitzgerald, G. A., Hsieh, Y.-T., Rougé, L., Litvinchuk, A., Steffek, M., Propson, N. E., Heffner, C. M., Discenza, C., et al. (2025) · Cell · doi:10.1016/j.cell.2024.10.027 · Cited by 91 · see citing works
Farmer, B. C., Williams, H. C., Devanney, N. A., Piron, M. A., Nation, G. K., Carter, D. J., Walsh, A. E., Khanal, R., Young, L. E. A., Kluemper, J. C., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00483-y · Cited by 87 · see citing works
Self-citationThe Proteome of Cholesteryl-Ester-Enriched Versus Triacylglycerol-Enriched Lipid Droplets
Khor, V. K., Ahrends, R., Lin, Y., Shen, W., Adams, C. M., Roseman, A. N., Cortez, Y., Teruel, M. N., Azhar, S., & Kraemer, F. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105047 · Cited by 86 · see citing works
Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice
Maezawa, I., Maeda, N., Montine, T. J., & Montine, K. S. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-10 · Cited by 81 · see citing works
Kien, B., Kolleritsch, S., Kunowska, N., Heier, C., Chalhoub, G., Tilp, A., Wolinski, H., Stelzl, U., & Haemmerle, G. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100172 · Cited by 81 · see citing works
Gallardo-Montejano, V. I., Yang, C., Hahner, L., McAfee, J. L., Johnson, J. A., Holland, W. L., Fernandez‐Valdivia, R., & Bickel, P. E. (2021) · Nature Communications · doi:10.1038/s41467-021-23601-2 · Cited by 73 · see citing works
APOE4 confers transcriptomic and functional alterations to primary mouse microglia
Machlovi, S. I., Neuner, S. M., Hemmer, B. M., Khan, R., Liu, Y., Huang, M., Zhu, J. D., Castellano, J. M., Cai, D., Marcora, E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105615 · Cited by 73 · see citing works
Huang, S., Zhang, Z., Cao, J., Yu, Y., & Pei, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01006-x · Cited by 72 · see citing works
Khan, S. A., Wollaston-Hayden, E. E., Markowski, T. W., Higgins, L., & Mashek, D. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m056812 · Cited by 64 · see citing works
Activation of STAT3 Regulates Reactive Astrogliosis and Neuronal Death Induced by AβO Neurotoxicity
Toral-Ríos, D., Patiño‐López, G., Gómez‐Lira, G., Gutiérrez, R., Becerril-Pérez, F., Rosales-Córdova, A., León‐Contreras, J. C., Hernández‐Pando, R., León‐Rivera, I., Soto‐Cruz, I., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207458 · Cited by 63 · see citing works
Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
Dai, J., Johnson, E. C. B., Dammer, E. B., Duong, D. M., Gearing, M., Lah, J. J., Levey, A. I., Wingo, T. S., & Seyfried, N. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00454 · Cited by 62 · see citing works
Dalhaimer, P. (2019) · Cells · doi:10.3390/cells8090974 · Cited by 52 · see citing works
Roberts, J. A., Varma, V. R., An, Y., Varma, S., Candia, J., Fantoni, G., Tiwari, V., Anerillas, C., Williamson, A., Saito, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8178 · Cited by 49 · see citing works
Eukaryotic lipid droplets: metabolic hubs, and immune first responders
Bosch, M., & Pol, A. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.12.006 · Cited by 48 · see citing works
Sorting nexin-4 regulates β-amyloid production by modulating β-site-activating cleavage enzyme-1
Kim, N., Cho, M., Won, S., Hoe-Jin, K., Yoon, S., & Kim, D. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0232-8 · Cited by 42 · see citing works
Altenburg, M. K., Johnson, L. A., Wilder, J., & Maeda, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610712200 · Cited by 36 · see citing works
Self-citationKloske, C. M., Dugan, A. J., Weekman, E. M., Winder, Z., Patel, E., Nelson, P. T., Fardo, D. W., & Wilcock, D. M. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab085 · Cited by 36 · see citing works
Johnson, L. A., Arbonés-Mainar, J. M., Fox, R. G., Pendse, A. A., Altenburg, M. K., Kim, H., & Maeda, N. (2011) · Diabetes · doi:10.2337/db11-0466 · Cited by 34 · see citing works
Self-citationTeixeira, L., Pereira-Dutra, F. S., dos Reis, P. R. P., Cunha‐Fernandes, T., Yoshinaga, M. Y., Souza‐Moreira, L., Souza, E. K., Barreto, E. A., Silva, T. P. D., Espinheira-Silva, H., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100984 · Cited by 34 · see citing works
He, Y., Dong, Y., Zhang, X., Ding, Z., Song, Y., Huang, X., Chen, S., Wang, Z., Ni, Y., & Ding, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.824235 · Cited by 31 · see citing works
Mhatre‐Winters, I., Eid, A., Han, Y., Tieu, K., & Richardson, J. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179829 · Cited by 26 · see citing works
Casey, C. A., Donohue, T. M., Kubik, J. L., Kumar, V., Naldrett, M. J., Woods, N. T., Frisbie, C. P., McNiven, M. A., & Thomes, P. G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100049 · Cited by 23 · see citing works
Zhu, Y., Kim, S. Q., Zhang, Y., Liu, Q., & Kim, K. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154861 · Cited by 22 · see citing works
de Leeuw, S. M., Kirschner, A. W. T., Lindner, K., Rust, R., Budny, V., Wolski, W. E., Gavin, A.-C., Nitsch, R. M., & Tackenberg, C. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.018 · Cited by 14 · see citing works
Triglyceride metabolism controls inflammation and APOE4-associated disease states in microglia
Stelzer, G. T. (2024) · doi:10.1242/prelights.38200 · Cited by 2 · see citing works
Triglyceride metabolism controls inflammation and APOE4 -associated disease states in microglia
Stephenson, R. A., Johnson, K. R., Cheng, L., Yang, L. G., Root, J. T., Gopalakrishnan, J., Shih, H.-Y., & Narayan, P. S. (2024) · doi:10.1101/2024.04.11.589145
Flagged first, then by citations
1 of the 76 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
APOE-Targeted Therapeutics for Alzheimer's Disease
Yassine, H. N., Hugo, C., O’Donovan, B., Stephens, I. O., Johnson, L. A., Cole, G. M., Julia, T. C. W., Johansson, J. O., Kisler, K., & Chiba‐Falek, O. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1388-25.2025 · Cited by 16 · see citing works
Self-citationStephens, I. O., & Johnson, L. A. (2025) · Cells · doi:10.3390/cells14221783 · Cited by 10 · see citing works
Self-citationMetabolic and inflammatory roles of glial cells in neurodegenerative and cerebrovascular diseases
OGUNLEYE, F. A., Zhou, Y., Yan, L., Abhulimen, P. O., Xu, Y., Lai, M. K. P., Okunowo, W. O., Sethi, G., Fang, C., & Ma, Y. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103120 · Cited by 10 · see citing works
Apolipoprotein E4 in Alzheimer’s Disease: Role in Pathology, Lipid Metabolism, and Drug Treatment
Al-Ghraiybah, N. F., Alkhalifa, A. E., Itokazu, Y., Farr, T., Pérez, N., Ali, H., & Kaddoumi, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021004 · Cited by 8 · see citing works
Cuní‐López, C., Root, J. T., Hao, Y., Kowal, I., Blomberg, N., Ghirlando, R., Yang, L. G., Hertog, S. K.-D., Cookson, M., van der Kant, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.19.669163 · Cited by 7 · see citing works
Haskell, A. K., Kulas, J. A., Carter, W., Javens‐Wolfe, J., Hinkel, R. D., Moussaif, M., Smiley, J. S., Lazaro, O., Robertson, S., Palkowitz, A. D., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71117 · Cited by 6 · see citing works
Petre, A. M., Thieschafer, J. S., Palsuledesai, C. C., Cornille, K., Chang, A., Li, L., & Distefano, M. D. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00320 · Cited by 3 · see citing works
Paraniak-Gieszczyk, B., & Ogłodek, E. A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100868 · Cited by 3 · see citing works
Ding, Y., Li, S.-Y., Zhang, W.-F., Chu, M.-M., Wang, X.-J., Zhang, Y., Zhang, H., Zhang, Y., Xu, L., Liu, X., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.017 · Cited by 2 · see citing works
Yuan, N. Y., Richards, W. D., Parham, K. T., Clark, S. G., & Lebakken, C. S. (2026) · Cells · doi:10.3390/cells15141266 · Cited by 2 · see citing works
Guo, H., Yang, Z., & Cheng, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837643 · Cited by 1 · see citing works
Li, Z., Ming, Q., Fu, L., Yang, J., Lv, Y., Chen, B., & Lu, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1886340 · Cited by 1 · see citing works
Kim, M. J., Blumenfeld, J. R., Li, Y., Yip, O., Yao, L., Ancheta, S., Leon, S. D., Platow, Z., Liang, Z., Shostak, D. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.04.692390 · Cited by 1 · see citing works
Cuní-López, C., Root, J. T., Hao, Y., Blomberg, N., Koppes-den Hertog, S. J., Sacks, D., Trujillo, A. E., Ghirlando, R., Kowal, I., Epstein, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76565-6
Nolt, G. L., MacLean, S. M., Golden, L. R., Thorpe, S. P., Stephens, I. O., Funnell, J. L., Brock, C. R., Lucido, C. C., Smith, L., Hernandez, G., et al. (2027) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.08.005
Self-citationBoisjoly, F., Majeur, D., Robb, J. L., Rodaros, D., & Alquier, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.18.695188
Role of apolipoprotein E4 in alzheimer’s disease pathogenesis and emerging therapeutic strategies
Natarajan, S., & Saraswathy, S. D. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01761-0
Lipid Droplets, ApoE, and Inflammatory Disease States
Melo, R. C. N., & Weller, P. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_36-1
APOE and Proteomics in Chronic Inflammation
Shvetcov, A., & Finney, C. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-52641-1_82-1
Salardini, A., Hashemiaghdam, A., O’Dell, R. S., Hillmer, A. T., Camacho, D. F., van Dyck, K. M., Nelsen, K., Ruan, A., Strittmatter, S. M., Carson, R. E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9012605/v1
Lipid Droplets, ApoE, and Inflammatory Disease States
Melo, R. C. N., & Weller, P. F. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_36
APOE and Proteomics in Chronic Inflammation
Shvetcov, A., & Finney, C. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_82
APOE interacts with COX-2 on lipid droplets to modulate inflammatory lipid signalingPreprint
Powers, A. E., Kamble, K., Nair, M., Windham, I. A., Miner, G. E., Prim, C. E., Mills, C. A., Lyons, S. P., Herring, L. E., Chirasani, V. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.09.730852
Self-citationKehmeier, M. N., Famiano, A., Cullen, A. E., Leonhardt, T., Ferguson, S. J., Snyder, M., McCurdy, C. E., Tyrrell, D. J., Alkayed, N. J., & Walker, A. E. (2026) · The Journal of Physiology · doi:10.1113/jp290852 · Cited by 1 · see citing works
Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer’s disease
Wu, J., Zhao, J. J., Chen, S. Y., & Xu, F. (2026) · Biological Research · doi:10.1186/s40659-026-00716-8
Targeting Microglial Receptors for Alzheimer’s Disease: Translational Barriers from Bench to Bedside
Tang, X., Hasan, I., & Xu, J. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2026-0008
Gao, H., Liu, H., Wan, S., Dan, Z., Xiong, J., Xing, Z., YIN, Y., Han, F., Yong, Y., TIAN, M., et al. (2026) · Environmental Pollution · doi:10.1016/j.envpol.2026.129015
Li, J., Jiang, L., 晁凤蕾, Zhang, L., 胡春年, Zhou, Y., Wang, S., Pan, Q., Luo, Y., Tang, J., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03907-7
Najt, C. P., Devarajan, M., Churchill, A., Kerr, E., Boatner, L., Gerrard, S. D., Fess, B., Guerrero, C. R., Higgins, L., Wendell, S. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.30.755694
ApoE lipidation state directs immunometabolic reprogramming of human microglia
Shiferaw, T. G., Sarkar, S., Baker, K. M., Wooldridge, R. S., Binfet, H. M., Prozapas, V. N., Ogbu, C. P., Schepmoes, A. A., Attah, I. K., Niemeyer, C. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71882 · Cited by 1 · see citing works
Shi, H., Zhao, Y., Wei, Z., Yan-jiang, W., & Bu, X.-L. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2026.09.009
Glial lipid reprogramming in brain aging: Lipid identity, organelle stress, and redox vulnerability
Rana, M., Ko, W., Nepali, K., Ko, C.-Y., Yen, T., Jan, J., Taliyan, R., Li, C.-H., & Yang, C. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104453
Zhang, H., Xiang, L., Zhang, L., Zhai, X., Yan, Y., Zhou, X., Zhang, Y., Yao, S., & Xia, Y. (2026) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1145/3841905.3841960
APOE-ε4 links CD8+ T cell infiltration to white matter inflammation in Alzheimer’s disease
Halters, S., Wildeman, J., van der Stok, H., van der Pol, S. M. A., Wessels, D. W. R., Karsten, M., den Haan, J. M. M., van Kesteren, R. E., Rozemüller, A. J. M., den Bossche, J. V., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00058-5
- Authors
- Friday, C. M., Stephens, I. O., Smith, C. T., Lee, S., Satish, D., Devanney, N. A., Cohen, S., Morganti, J. M., Gordon, S. M., & Johnson, L. A.
- Affiliations
- University of Kentucky (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Johnson, Lance A.
- ORCID
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2025-08
- Volume
- 212
- Pages
- 106983
- ISSN
- 0969-9961 (ISSN-L)
- PMC
- PMC12187248
- OpenAlex
- W4410877579
- Semantic Scholar
- e98e0049b5c5598c1e05b1a5347c7b8e757d4759
- Cited by
- 33
- References
- 76
- Citations by year
- 2026: 24 · 2025: 9
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neurobiology of Disease (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- UKnowledge (University of Kentucky) (submittedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNC Libraries
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK133184)
- National Institutes of Health
- California Missions Foundation
- National Institute on Aging (RF1NS118558, R01AG070830, R01AG080589, R01AG081421-S1, R01AG062550)
- Alzheimer's Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- APOE ε4, lipid droplets, Alzheimer's disease, microglial inflammation, hepatic lipid droplets, phosphatidylcholine, lipopolysaccharide response, fatty acid beta-oxidation, vesicle trafficking, inflammatory cytokines, necroptosis, APOE3, neuroinflammation
- MeSH terms
- Alzheimer Disease, Animals, Humans, Inflammation, Lipopolysaccharides, Male, Mice, Inbred C57BL, Mice, Transgenic, Microglia, Proteome, Mice, Apolipoprotein E4, Lipid Droplets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-11-02.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-11-02.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
